



05-31-06

Response under 37 CFR 1.116
Expedited Procedure. ART UNIT

AF/IFW 1621

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner of Patents
Alexander, Va. 22313-1450

May 29, 2006

Corres. and Mail
BOX AF

Applicant: Reuben E. DeLoach

Number: 10 / 813384

RPA Filed: March 30, 2004 (Express mail)

RPA Title: "Hydrazide substrate safely shuts down disease activated protease to halt viral replication, cancerous cell division, and toxic protein generation"

Examiner: Mr. Brian J. Davis, Art Unit 1621

DO NOT ENTER
BJD
6/4/06
Sir:

Amendment Under Rule 116

Assistant Commissioner of Patents
Alexander, Va. 22313-1450

In response to the Office Action post marked March 29, 2006, the applicant requests that the above referenced application be amended as follows:

SPECIFICATION:

1. The applicant requests that page 1, paragraph [0002], be replaced with the following paragraph:
[0002] The field of endeavor to which this invention pertains is hydrazide substrate drugs as used in prior art applications to shutdown oxidase protein production as an antidepressant method, and herewith such drugs are used to shutdown proteins as viral coat, cancer metastatic, and abnormal cell proteins for disease treatment purposes, and additionally used to shutdown proteins produced by microorganism to provide an antibiotic purpose.

2. The applicant requests that page 1, paragraph [0004], the first sentence be replaced by the following:
[0004] This invention provides a new purpose for the use of existing drugs of the mono amine oxidase enzyme inhibitor (MAOI) class that utilizes an irreversible substrate mechanism.